Pharmaceuticals News and Research

RSS

CureDM receives patent allowance for novel islet neogenesis program

CureDM, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering a Human proIslet Peptide (HIP) and methods related to its use and administration for treating type 1 diabetes.

15 Dec 2009

Mylan to be added to NASDAQ-100 Index

Mylan Inc. today announced that the company will be added to the NASDAQ-100 Index Dec. 21. Mylan's common shares will also be included in NASDAQ's PowerShares QQQ.

15 Dec 2009

USPTO issues Notice of Allowance to Transcept Pharmaceuticals for Intermezzo claims

Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate.

15 Dec 2009

Decision Resources: Atrial fibrillation drug market to increase more than sevenfold

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the launches of several new agents, the atrial fibrillation drug market will increase more than sevenfold from $790 million in 2008 to $6.1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

15 Dec 2009

New program to help maintain bone health in men with prostate cancer on ADT announced

Watson Pharmaceuticals, Inc. today announced a new program encouraging health professionals to help maintain the bone health of prostate cancer patients who are on long-term androgen deprivation therapy (ADT).

15 Dec 2009

Rexahn Pharmaceuticals and TheraTarget sign joint research collaboration agreement

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, and TheraTarget, Inc., a developer of innovative polymer therapeutics for the treatment of cancer, today announced the formation of a joint research collaboration agreement.

15 Dec 2009

Manchester Pharmaceuticals' Chenodal now available for patients suffering from gallstones

Manchester Pharmaceuticals, Inc.(TM) announced today the availability of Chenodal(TM) 250 mg (chenodiol tablets). On October 22, 2009, the US Food and Drug Administration (FDA) approved Chenodal, an important therapy for patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

15 Dec 2009

Bio-Quant becomes wholly-owned subsidiary of NexMed

NexMed, Inc., a developer of products based on the NexACT® technology, today announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA. Upon closing, Bio-Quant became a wholly-owned subsidiary of NexMed.

15 Dec 2009

Dyadic International enters into collaboration agreement with The Scripps Research Institute

Dyadic International, Inc. ("Dyadic") announced today that it has extended its collaboration with The Scripps Research Institute ("Scripps") by entering into an agreement with Scripps to re-annotate the genome of Dyadic's patented and proprietary C1 fungus ("C1").

15 Dec 2009

Teva Pharmaceutical Industries receives approval for newly revised prescribing information for AZILECT

Teva Pharmaceutical Industries, Ltd. today announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information for AZILECT® (rasagiline tablets) reducing medication and food restrictions.

15 Dec 2009

Updated clinical data from Phase 2 study evaluating oral ridaforolimus presented

ARIAD Pharmaceuticals, Inc. today announced the presentation of updated clinical data from its Phase 2 study evaluating oral ridaforolimus in combination with trastuzumab (Herceptin®) in patients with resistant, metastatic breast cancer.

15 Dec 2009

Alexza Pharmaceuticals submits its NDA for Staccato loxapine to FDA

Alexza Pharmaceuticals, Inc. today announced that it has submitted its New Drug Application (NDA) for Staccato® loxapine (AZ-004) to the US Food and Drug Administration (FDA).

15 Dec 2009

Vion Pharmaceuticals receives complete response letter related to its NDA for Onrigin injection

VION PHARMACEUTICALS, INC. today announced that it had received a complete response letter from the U.S. Food and Drug Administration ("FDA") related to its New Drug Application ("NDA") for Onrigin(TM) (laromustine) injection submitted in February 2009.

14 Dec 2009

Data mining by drug companies raises concern

The Los Angeles Times examines a practice called data mining in which drug companies track how doctors prescribe medications by obtaining data from pharmacies and health insurers.

14 Dec 2009

Alcon signs definitive agreement to acquire Optonol

Alcon announced today that it has entered into a definitive agreement to acquire Optonol, Ltd., a medical device company that develops, manufactures and markets novel miniature surgical implants used to lower intraocular pressure (IOP) in patients with glaucoma.

14 Dec 2009

Companies shed more light on health bill lobbying

USA Today: "Sweeping ethics rules passed by Congress in 2007 require corporate interests that lobby Washington to reveal more information than ever, such as how much they donate to politicians' favorite charities.

14 Dec 2009

Clarient and BioView team up to develop diagnostic tool for early detection of lung cancer

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, and BioView Ltd. (TASE: BIOV) today jointly announced that they will collaborate on studies to validate the clinical utility of a non-invasive test for the early detection of non-small cell lung cancer.

14 Dec 2009

Pharmaceuticals News and Research

CureDM receives patent allowance for novel islet neogenesis program

Mylan to be added to NASDAQ-100 Index

USPTO issues Notice of Allowance to Transcept Pharmaceuticals for Intermezzo claims

Decision Resources: Atrial fibrillation drug market to increase more than sevenfold

New program to help maintain bone health in men with prostate cancer on ADT announced

Rexahn Pharmaceuticals and TheraTarget sign joint research collaboration agreement

Manchester Pharmaceuticals' Chenodal now available for patients suffering from gallstones

Bio-Quant becomes wholly-owned subsidiary of NexMed

Dyadic International enters into collaboration agreement with The Scripps Research Institute

Teva Pharmaceutical Industries receives approval for newly revised prescribing information for AZILECT

Updated clinical data from Phase 2 study evaluating oral ridaforolimus presented

Alexza Pharmaceuticals submits its NDA for Staccato loxapine to FDA

Vion Pharmaceuticals receives complete response letter related to its NDA for Onrigin injection

Data mining by drug companies raises concern

Alcon signs definitive agreement to acquire Optonol

Companies shed more light on health bill lobbying

Clarient and BioView team up to develop diagnostic tool for early detection of lung cancer

New technological system to help improve availability of anti-malarial drugs in Tanzania

Allen & Caron selected as Ohr Pharmaceutical's agency for investor relations

New eCTD document service speeds up drug approval process

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence